CBD Denver (CBDD) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: -16.53%
• EPS Growth: -100.00%
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Specialty Retail
• EPS (TTM): 0.00
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.36
• Price to Book (P/B): -2.18
• Price to Sales (P/S): 0.78
• P/FCF Ratio: -33.19
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: ―

CBD Denver faces significant financial and operational challenges, with high leverage and cash flow issues as primary concerns. The lack of technical indicators and an extremely high P/E ratio indicate potential overvaluation. Limited information from the earnings call adds uncertainty, resulting in a low overall stock score.

Positive Factors

Product Diversification

A diverse product range allows CBD Denver to cater to various consumer preferences, enhancing market reach and reducing dependency on a single product line.

Strategic Partnerships

Strategic partnerships help CBD Denver achieve cost efficiencies and maintain high product quality, which can lead to improved margins and competitive advantage.

Revenue Channels

Multiple revenue channels provide CBD Denver with a stable income stream, reducing risk associated with reliance on a single sales avenue and supporting long-term growth.

Negative Factors

High Debt Levels

High leverage and negative equity indicate financial risk, potentially limiting CBD Denver's ability to invest in growth opportunities and affecting long-term stability.

Negative Cash Flow

Negative operating cash flow suggests cash management issues, which could hinder CBD Denver's ability to fund operations and invest in future growth without external financing.

Volatile Revenue Trends

Volatile revenue trends indicate instability in market demand or operational execution, which could challenge CBD Denver's ability to achieve consistent growth.

CBD Denver Business Overview & Revenue Model

Company Description

CBD of Denver Inc. engages in developing and commercializing cannabidiol (CBD) products. It is involved in the research, development, and distribution of premium hemp extract products. The company was formerly known as Verde Media Group, Inc. and changed its name to CBD of Denver Inc. in 2018. CBD of Denver Inc. is based in Centennial, Colorado. CBD of Denver Inc. operates as a subsidiary of Swiss Industry Ventures AG.

How the Company Makes Money

CBD Denver makes money primarily through the sale of its CBD-infused products to both retail and wholesale customers. The company generates revenue by distributing its products through various channels, including online direct-to-consumer sales, partnerships with retail stores, and collaborations with distributors who supply to health and wellness outlets. Additionally, CBD Denver may engage in private labeling agreements, where it produces CBD products under different brand names for other companies, further diversifying its revenue streams. Strategic partnerships with hemp growers and technology providers for extraction processes also contribute to cost efficiencies and product quality, enhancing the company's profitability.

CBD Denver Financial Statement Overview

Summary

CBD Denver's financial performance shows some improvement in net income, but challenges remain with volatile revenue trends, negative EBIT margin, a high debt-to-equity ratio, and negative operating cash flow.

Income Statement

CBD Denver shows some improvement in net income with a positive result in 2023 compared to prior years of losses. However, the company has experienced volatile revenue trends, with a significant decrease in revenue from 2021 to 2022, and a marginal increase in 2023. Margins remain a concern, with a negative EBIT margin in 2023, indicating ongoing operational challenges.

Balance Sheet

The balance sheet reveals a concerning financial position, with negative stockholders' equity in recent years, indicating potential solvency issues. The company has a high debt-to-equity ratio, exacerbated by negative equity, suggesting significant leverage and financial risk.

Cash Flow

Operating cash flow remains negative, indicating cash management issues, despite some improvement in 2023. Free cash flow data is incomplete, limiting analysis. The positive shift in financing cash flow points to reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.42M	3.75M	2.98M	2.34M	22.85M	15.99M
Gross Profit	199.01K	218.16K	165.48K	-670.00K	240.52K	1.41M
EBITDA	232.44K	85.25K	865.66K	-3.03M	-63.44K	1.21M
Net Income	98.44K	-79.93K	583.58K	-3.25M	-236.00K	779.14K
Balance Sheet
Total Assets	8.52K	40.76K	128.30K	28.04K	1.97M	2.74M
Cash, Cash Equivalents and Short-Term Investments	8.52K	35.12K	36.55K	28.04K	91.51K	82.65K
Total Debt	979.65K	1.06M	1.06M	949.38K	781.68K	253.21K
Total Liabilities	1.35M	1.38M	1.48M	2.00M	1.72M	1.94M
Stockholders Equity	-1.34M	-1.34M	-1.35M	-1.97M	247.66K	798.37K
Cash Flow
Free Cash Flow	-143.12K	-87.85K	-31.44K	-759.21K	-723.90K	60.95K
Operating Cash Flow	-143.12K	-87.85K	-31.44K	-759.21K	-723.90K	60.95K
Investing Cash Flow	0.00	0.00	11.08K	0.00	0.00	-15.98K
Financing Cash Flow	13.10K	86.42K	10.97K	731.00K	855.49K	310.00

CBD Denver Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TIVC	43 Neutral	$3.92M	-0.20	-178.18%	―	-49.63%	82.22%
YCBD	40 Underperform	$7.21M	-0.13	-33.13%	―	-7.80%	90.17%
CBDD	37 Underperform	―	―	―	―	-16.53%	-100.00%
BJDX	29 Underperform	$2.14M	-0.04	-126.20%	―	―	97.70%
DRMA	15 Underperform	$2.09M	-0.08	-203.36%	―	―	90.53%